Angela Subbiani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Angela Subbiani has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Morandi
University of Florence
8 shared publications - Elisabetta Romano
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
8 shared publications - Marina Bacci
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
8 shared publications - Nicla Lorito
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
8 shared publications - Alfredo Smiriglia
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
7 shared publications - Andrea Botticelli
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00185 Rome, Italy
7 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 3, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537C and T47D Y537C cells
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 3, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537C and T47D Y537C cells
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Data from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction.Significance:ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction.Significance:ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
RSL3 and erastin do not exhibit synergistic effects with elacestrant or fulvestrant treatment in MCF7-LTED WT cells
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
RSL3 and erastin do not exhibit synergistic effects with elacestrant or fulvestrant treatment in MCF7-LTED WT cells
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 4, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537S and MCF7 Y537N cells
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 4, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537S and MCF7 Y537N cells
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 2, showing that ACSL4 targeting prevents ferroptosis execution in MCF7-LTED Y537C cells
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 2, showing that ACSL4 targeting prevents ferroptosis execution in MCF7-LTED Y537C cells
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
ChIP-seq data relative to ESR1-mutant and its neomorphic transcriptional activity in regulating ACSL4, a feature linked to transcriptional reprogramming associated with ferroptosis
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
ChIP-seq data relative to ESR1-mutant and its neomorphic transcriptional activity in regulating ACSL4, a feature linked to transcriptional reprogramming associated with ferroptosis
- 7 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (3) , 679-692
ESR1 -Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction. Significance: ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.
- 7 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (3) , 679-692
ESR1 -Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction. Significance: ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.
- Open Access
- 26 June 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (7) , 1533-1559
FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer
Triple-negative breast cancer (TNBC) has limited therapeutic options, is highly metastatic and characterized by early recurrence. Lipid metabolism is generally deregulated in TNBC and might reveal vulnerabilities to be targeted or used as biomarkers with clinical value. Ferroptosis is a type of cell death caused by iron-dependent lipid peroxidation which is facilitated by the presence of polyunsaturated fatty acids (PUFA). Here we identify fatty acid desaturases 1 and 2 (FADS1/2), which are responsible for PUFA biosynthesis, to be highly expressed in a subset of TNBC with a poorer prognosis. Lipidomic analysis, coupled with functional metabolic assays, showed that FADS1/2 high-expressing TNBC are susceptible to ferroptosis-inducing agents and that targeting FADS1/2 by both genetic interference and pharmacological approach renders those tumors ferroptosis-resistant while unbalancing PUFA/MUFA ratio by the supplementation of exogenous PUFA sensitizes resistant tumors to ferroptosis induction. Last, inhibiting lipid droplet (LD) formation and turnover suppresses the buffering capacity of LD and potentiates iron-dependent cell death. These findings have been validated in vitro and in vivo in mouse- and human-derived clinically relevant models and in a retrospective cohort of TNBC patients.
- 26 June 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (7) , 1533-1559
Open AccessFADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer
Triple-negative breast cancer (TNBC) has limited therapeutic options, is highly metastatic and characterized by early recurrence. Lipid metabolism is generally deregulated in TNBC and might reveal vulnerabilities to be targeted or used as biomarkers with clinical value. Ferroptosis is a type of cell death caused by iron-dependent lipid peroxidation which is facilitated by the presence of polyunsaturated fatty acids (PUFA). Here we identify fatty acid desaturases 1 and 2 (FADS1/2), which are responsible for PUFA biosynthesis, to be highly expressed in a subset of TNBC with a poorer prognosis. Lipidomic analysis, coupled with functional metabolic assays, showed that FADS1/2 high-expressing TNBC are susceptible to ferroptosis-inducing agents and that targeting FADS1/2 by both genetic interference and pharmacological approach renders those tumors ferroptosis-resistant while unbalancing PUFA/MUFA ratio by the supplementation of exogenous PUFA sensitizes resistant tumors to ferroptosis induction. Last, inhibiting lipid droplet (LD) formation and turnover suppresses the buffering capacity of LD and potentiates iron-dependent cell death. These findings have been validated in vitro and in vivo in mouse- and human-derived clinically relevant models and in a retrospective cohort of TNBC patients.
- Open Access
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma
Osteosarcoma (OS) is the most common primary malignancy of the bone, highly aggressive and metastasizing, and it mainly affects children and adolescents. The current standard of care for OS is a combination of surgery and chemotherapy. However, these treatment options are not always successful, especially in cases of metastatic or recurrent osteosarcomas. For this reason, research into new therapeutic strategies is currently underway, and immunotherapies have received considerable attention. Mifamurtide stands out among the most studied immunostimulant drugs; nevertheless, there are very conflicting opinions on its therapeutic efficacy. Here, we aimed to investigate mifamurtide efficacy through in vitro and in vivo experiments. Our results led us to identify a new possible target useful to improve mifamurtide effectiveness on metastatic OS: the cytokine interleukin-10 (IL-10). We provide experimental evidence that the synergic use of an anti-IL-10 antibody in combination with mifamurtide causes a significantly increased mortality rate in highest-grade OS cells and lower metastasis in an in vivo model compared with mifamurtide alone. Overall, our data suggest that mifamurtide in combination with an anti-IL-10 antibody could be proposed as a new treatment protocol to be studied to improve the outcomes of OS patients.
Open AccessBlockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma
Osteosarcoma (OS) is the most common primary malignancy of the bone, highly aggressive and metastasizing, and it mainly affects children and adolescents. The current standard of care for OS is a combination of surgery and chemotherapy. However, these treatment options are not always successful, especially in cases of metastatic or recurrent osteosarcomas. For this reason, research into new therapeutic strategies is currently underway, and immunotherapies have received considerable attention. Mifamurtide stands out among the most studied immunostimulant drugs; nevertheless, there are very conflicting opinions on its therapeutic efficacy. Here, we aimed to investigate mifamurtide efficacy through in vitro and in vivo experiments. Our results led us to identify a new possible target useful to improve mifamurtide effectiveness on metastatic OS: the cytokine interleukin-10 (IL-10). We provide experimental evidence that the synergic use of an anti-IL-10 antibody in combination with mifamurtide causes a significantly increased mortality rate in highest-grade OS cells and lower metastasis in an in vivo model compared with mifamurtide alone. Overall, our data suggest that mifamurtide in combination with an anti-IL-10 antibody could be proposed as a new treatment protocol to be studied to improve the outcomes of OS patients.
- Open Access
- 13 August 2020
- Published by Hindawi Limited in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-11
Beta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression
The use of nutraceuticals during cancer treatment is a long-lasting debate. Berberine (BBR) is an isoquinoline quaternary alkaloid extracted from a variety of medicinal plants. BBR has been shown to have therapeutic effects in different pathologies, particularly in cancer, where it affects pathways involved in tumor progression. In neuroblastoma, the most common extracranial childhood solid tumor, BBR, reduces tumor growth by regulating both stemness and differentiation features and by inducing apoptosis. At the same time, the inhibition of β-adrenergic signaling leads to a reduction in growth and increase of differentiation of neuroblastoma. In this review, we summarize the possible beneficial effects of BBR in counteracting tumor growth and progression in various types of cancer and, in particular, in neuroblastoma. However, BBR administration, besides its numerous beneficial effects, presents a few side effects due to inhibition of MAO A enzyme in neuroblastoma cells. Therefore, herein, we proposed a novel therapeutic strategy to overcome side effects of BBR administration consisting of concomitant administration of BBR together with β-blockers in neuroblastoma.
- 13 August 2020
- Published by Hindawi Limited in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-11
Open AccessBeta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression
The use of nutraceuticals during cancer treatment is a long-lasting debate. Berberine (BBR) is an isoquinoline quaternary alkaloid extracted from a variety of medicinal plants. BBR has been shown to have therapeutic effects in different pathologies, particularly in cancer, where it affects pathways involved in tumor progression. In neuroblastoma, the most common extracranial childhood solid tumor, BBR, reduces tumor growth by regulating both stemness and differentiation features and by inducing apoptosis. At the same time, the inhibition of β-adrenergic signaling leads to a reduction in growth and increase of differentiation of neuroblastoma. In this review, we summarize the possible beneficial effects of BBR in counteracting tumor growth and progression in various types of cancer and, in particular, in neuroblastoma. However, BBR administration, besides its numerous beneficial effects, presents a few side effects due to inhibition of MAO A enzyme in neuroblastoma cells. Therefore, herein, we proposed a novel therapeutic strategy to overcome side effects of BBR administration consisting of concomitant administration of BBR together with β-blockers in neuroblastoma.